A First in Human Study of theMenin-KMT2A (MLL1)Inhibitor JNJ-75276617 in Participants with Acute Leukemia
Brief description of study
The primary objectives of this study are to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-75276617, as well as the safety and tolerability at the RP2D(s). Secondary objectives are to provide a further understanding of how the study drug JNJ-75276617 works for assessing preliminary clinical activity. The study drug JNJ-75276617 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.